

1 **Incidence Rates of Medically Attended COVID-19 in Infants Less than 6 Months of Age**

2
3 Isabel Griffin, PhD, MPH^a, Stephanie A. Irving, MHS^b, Carmen Sofia Arriola, PhD^a, Angela P.
4 Campbell, MD, MPH^a, De-Kun Li, MD, PhD^c, Fatimah S. Dawood, MD^a, Caroline Doughty-
5 Skierski^d, Jeannette R. Ferber, MPH^c, Nickolas Ferguson^e, Louise Hadden^e, Jillian T.
6 Henderson^b, Mary Juergens^e, Venkatesh Kancharla^d, Allison L. Naleway^b, Gabriella Newes-
7 Adeyi^e, Erin Nicholson^d, Roxana Odouli, MSPH^c, Lawrence Reichle^e, Mo Sanyang^d, Kate
8 Woodworth, MD, MPH^a, Flor M. Munoz^d

9
10 **Affiliations:**

11 ^aCenters for Disease Control and Prevention, Atlanta, Georgia; and

12 ^bCenter for Health Research, Kaiser Permanente Northwest, Portland, Oregon; and

13 ^cKaiser Permanente Northern California, Oakland, California; and

14 ^dBaylor College of Medicine, Houston, Texas; and

15 ^eAbt Associates, Inc, Rockville, MD

16

17

18 **Address correspondence to:** Carmen Sofia Arriola, Influenza Division, Centers for Disease
19 Control and Prevention, 1600 Clifton Rd MS A-32, Atlanta, GA 30329, United States;
20 telephone: (404) 718-4589; fax (404) 639-3866; email: wus3@cdc.gov.

21

22 **Short title:** Incidence Rates of COVID-19 in Infants

23

24 **Conflict of Interest Disclosures (includes financial disclosures):** Author A. Naleway reports
25 institutional support from Pfizer and Vir Biotechnology. All other authors have indicated that
26 they have no conflicts of interest or financial relationships relevant to this article to disclose.

27

28 **Other Disclosures:** The findings and conclusions in this report are those of the authors and do
29 not necessarily represent the official position of the Centers for Disease Control and Prevention
30 (CDC).

31

32 **Funding/Support:** This study was funded by the US Centers for Disease Control and
33 Prevention (CDC) through Contract # 75D30120C08150 with Abt Associates.

34

35 **Role of Funder/Sponsor:** This study was funded by the US Centers for Disease Control and
36 Prevention (CDC). CDC-affiliated authors were involved in study design, data collection,
37 analysis and interpretation, report writing, and the decision to submit the paper for
38 publication. The corresponding author had full access to all data used in the analysis and had
39 final responsibility for the decision to submit for publication.

40

41 **Abbreviations:** COVID-19—coronavirus disease 2019, SARS-CoV-2 – severe acute
42 respiratory syndrome coronavirus 2, RT-PCR—Reverse Transcription Polymerase Chain
43 Reaction.

44

45

46 **Article Summary**

47 This report describes incidence rates and characteristics of medically attended outpatient and
48 inpatient COVID-19 episodes among infants aged <6 months during the COVID-19 pandemic.

49

50 **What's Known on This Subject**

51 Surveillance data and case series suggest that infants aged <1 year may be more likely to be
52 hospitalized with COVID-19 than older children, but few data are available about the risk of
53 medically attended COVID-19 episodes among infants.

54

55 **What this Study Adds**

56 Among infants aged <6 months, few were hospitalized with COVID-19. Incidence rates of
57 medically attended COVID-19 episodes were highest among infants aged ≤ 1 month and among
58 infants of women with COVID-19 during the 6 month post-partum period.

59

60

61

62

63

64

Contributors' Statement Page

65

66 Dr. Dawood, Dr. Arriola, Dr Campbell, Dr Li, Dr Henderson, Ms. Irving, Dr. Naleway, Dr.
67 Munoz, and Dr. Nicholson conceptualized and designed the study and data collection
68 procedures.

69

70 Dr. Woodworth conceptualized and designed the analysis, drafted the initial manuscript, and
71 reviewed and revised the manuscript.

72

73 Dr. Griffin conceptualized and designed the analysis, carried out all analyses, drafted the initial
74 manuscript, and reviewed and revised the manuscript.

75

76 Ms. Doughty-Skierski, Ms. Ferber, Mr. Kancharla, Ms. Irving, Ms. Odouli, Mr Sanyang, Dr.
77 Newes-Adeyi, Ms. Juergens, Mr. Ferguson, Ms. Hadden and Mr. Reichle collected data and
78 provided data for this analysis.

79

80 All authors critically reviewed and revised the manuscript, approved the final manuscript as
81 submitted and agree to be accountable for all aspects of the work.

82

83

84

85

86

87

88

89

90

91

92 **Abstract**

93

94 **Objective**

95 Studies suggest infants may be at increased risk of severe COVID-19 relative to older children,
96 but few data exist regarding the incidence of COVID-19 episodes and associated risk factors. We
97 estimate incidence rates and describe characteristics associated with medically attended COVID-
98 19 episodes among infants younger than 6 months of age.

99

100 **Methods**

101 We analyzed electronic medical record data from a cohort of infants born March 1, 2020–
102 February 28, 2021. Data from three health care delivery systems included demographic
103 characteristics, maternal and infant outpatient visit and hospitalization diagnoses, and SARS-
104 CoV-2 test results. Medically attended COVID-19 episodes were defined by positive SARS-
105 CoV-2 clinical tests and/or COVID-19 diagnosis codes during medical care visits. Unadjusted
106 and site-adjusted incidence rates by infant month of age, low and high SARS-CoV-2 circulation
107 periods and maternal COVID-19 diagnosis were calculated.

108

109 **Results**

110 Among 18,192 infants aged <6 months whose mothers received prenatal care within the three
111 systems, 173 (1.0%) had medically attended COVID-19 episodes. Incidence rates were highest
112 among infants aged under 1 month (2.0 per 1,000 person-weeks) and 1 month (2.0 per 1,000
113 person-weeks) compared with older infants. Incidence rates were also higher for infants born to
114 women with postpartum COVID-19 compared with women without known COVID-19 and
115 women diagnosed with COVID-19 during pregnancy.

116

117 **Conclusion**

118 Most medically attended COVID-19 episodes in infants aged <6 months were outpatient care
119 encounters. Infants of women with postpartum COVID-19 had a higher risk of medically attended
120 COVID-19 than infants born to mothers who were diagnosed during pregnancy or never diagnosed
121 underscoring the importance of COVID-19 prevention measures for their household members and
122 caregivers to prevent infections in infants.

123

124

125 Early in the coronavirus disease 2019 (COVID-19) pandemic, surveillance data
126 suggested that COVID-19 was infrequent and mild in children but that hospitalization rates
127 among infants aged <1 year might be higher than among older children.¹ More recent studies
128 suggest that infants aged less than one year of age primarily experience mild to moderate
129 COVID-19, but represent a disproportionate amount of pediatric COVID-19 associated
130 hospitalizations.^{2,3,4,5,6} However, most published studies to date describing severe acute

131 respiratory syndrome-related coronavirus (SARS-CoV-2) infection among infants are based on
132 convenience samples with small numbers of infants that preclude examining outcomes by age
133 group and lack population denominators that allow an assessment of true community risk.
134 Estimates of incidence rates of medically attended COVID-19 episodes among infants, including
135 outpatient care encounters, could help guide risk communication for expectant and new parents
136 and might inform future public health recommendations for this group.

137 The Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network: Electronic
138 Cohort (eESPI) collected electronic medical record data for a retrospective cohort of pregnant
139 persons and their infants who were born during the COVID-19 pandemic. Data about infants were
140 collected up until the date they turned six months old. We analyzed data from the eESPI pregnancy
141 and infant cohort to describe infants <6 months of age with and without medically attended
142 COVID-19 episodes including both hospitalizations and outpatient care encounters (including
143 urgent care and emergency department encounters). Additionally, we estimated incidence rates of
144 medically attended COVID-19 episodes overall and by level of SARS-CoV-2 circulation, site, age
145 group, and maternal COVID-19 diagnosis during pregnancy and the six month postpartum period.

146

147 METHODS

148 Study design and population

149 The eESPI study was conducted at three healthcare delivery systems in the United States:
150 Kaiser Permanente Northwest (Portland, OR), Kaiser Permanente Northern California (Oakland,
151 CA), and Baylor College of Medicine (Houston, TX). Persons were eligible for inclusion in the
152 maternal cohort if they 1) had an estimated delivery date (EDD) from March 1, 2020 through
153 February 28, 2021 excluding women with pregnancy losses that occurred prior to March 1, 2020

154 and 2) had at least one prenatal care outpatient or telemedicine visit within the respective health
155 system from December 1, 2019 through February 28, 2021. The infant cohort included all live
156 born infants of individuals included in the maternal cohort. This analysis included all infants
157 born from March 1, 2020 through February 28, 2021.

158 Data collection

159 Data were extracted from electronic medical records using standardized variable
160 definitions across study sites (see Supplemental Methods Data Dictionary – Appendix A and
161 Appendix B). Most variables were defined by one or more International Classifications of
162 Diseases 10 (ICD-10) codes. Data collection included maternal and infant demographic
163 characteristics, maternal prenatal visit history, maternal and infant medical conditions, diagnosis
164 codes for all telemedicine, emergency department (ED), and ambulatory care encounters and
165 hospitalizations, and results from all SARS-CoV-2 RT-PCR testing. For this study, data about
166 infants were collected from birth until they turned six months of age or their age as of February
167 28, 2021, whichever occurred first.

168 Analysis definitions

169 All variables derived from ICD-10 codes can be found in Appendix A and Appendix B.
170 Medically attended COVID-19 episodes in infants, including telemedicine, ED, and ambulatory
171 care encounters, were identified based on at least one of the following: 1) a positive RT-PCR test
172 for SARS-CoV-2 within three days of a medical encounter, or 2) a COVID-19 diagnostic code
173 (ICD-10: U07.1) (Appendix A). Hospitalizations for any reason were counted if they met the test
174 and diagnostic criteria described above.

175 Maternal race/ethnicity was extracted from electronic medical records and classified as
176 Hispanic/Latina, non-Hispanic White, non-Hispanic Black, and non-Hispanic Other. The non-
177 Hispanic Other race/ethnicity category included American Indian or Alaska Native, Asian,
178 Native Hawaiian or Pacific Islander, and women who had more than one race listed in their
179 medical record. A list of conditions determined to be underlying medical conditions for mothers
180 and infants can be found in the Supplemental Methods Data Dictionary (Appendix B). Timing of
181 underlying medical conditions for infants was based on timing relative to any COVID-19
182 diagnosis or positive test. Timing of COVID-19 for mothers was determined based on either a
183 documented positive RT-PCR or antigen test for SARS-CoV-2 or COVID-19 diagnostic code
184 during pregnancy or during the postpartum period (two mothers had COVID-19 documented
185 during both pregnancy and the postpartum period). The postpartum period was defined as the six
186 months immediately following delivery.

187 Gestational age at delivery (preterm [<37 weeks] or term/post-term [≥ 37 weeks]) was
188 determined using reported gestational age at delivery or derived from delivery date and estimated
189 date of conception (Appendix A). High and low SARS-CoV-2 circulation weeks were defined
190 for each site as weeks with case counts above the median case count (high) or below the median
191 case count (low) for the study period, using Health and Human Services (HHS) representative
192 county-level surveillance data for Texas (Harris County), Oregon (Multnomah County), and
193 California (Santa Clara County) in each health system's service area.⁷

194

195 Analysis

196 Frequencies of maternal and infant characteristics were described for infants with and
197 without medically attended COVID-19 episodes. Available characteristics of interest included
198 maternal race/ethnicity, maternal Medicaid status, maternal COVID-19 diagnosis (during
199 pregnancy, during the six month postpartum period, or both during pregnancy and the postpartum
200 period), gestational age at birth, infant sex, presence of any underlying medical conditions for
201 mother and infant, and site. Unadjusted chi-square and fisher's exact test p-values of ≤ 0.05 were
202 considered statistically significant.

203 For incidence rate calculations, an aggregate crude incidence rate for the full cohort was
204 calculated with the total number of infants with medically attended COVID-19 episodes as the
205 numerator and the total number of person-weeks at risk that each infant (those with and without
206 medically attended COVID-19 episodes) was in the cohort as the denominator. Site-adjusted
207 negative binomial models were then used to estimate incidence per 1,000 person-weeks and
208 95% confidence intervals by infant sex, maternal race/ethnicity, maternal Medicaid status,
209 presence of any underlying medical conditions for mother and infant, age in months (<1 month,
210 1 month, 2 months, 3 months, 4 months, and 5 months of age), maternal SARS-CoV-2 infection
211 status (no infection, infection during pregnancy or infection during the six-month postpartum
212 period), and low or high SARS-CoV-2 circulation in the community.

213 All analyses were conducted in SAS Version 9.4.

214 *Ethical Review*

215 This protocol was reviewed by the Institutional Review Boards of participating sites. This
216 activity was reviewed by CDC and was conducted consistent with applicable federal law and
217 CDC policy.

218

219 RESULTS

220 Among 18,192 infants aged less than six months of age in the cohort, 173 (1.0%) had
221 medically attended COVID-19 episodes, including 114 (65.9%) identified by positive SARS-CoV-
222 2 laboratory testing and 59 (34.1%) by COVID-19 diagnosis code only without a documented
223 laboratory-test in the medical record. Medically attended COVID-19 episodes were more frequent
224 among infants from site B (1.4% of 7,434 infants) compared with those from sites A and C (site A
225 0.8% of 4,794 infants and site C 0.5% of 5,964 infants) (Table 1). There were no differences
226 between infants with versus without medically attended COVID-19 episodes by infant sex or
227 gestational age at birth. However, compared to infants without medically attended COVID-19, a
228 larger proportion of infants with medically attended COVID-19 episodes were infants of Hispanic
229 mothers (46.8% vs. 27.9%, <0.0001), Medicaid beneficiaries (29.5% vs. 22.4%, p=0.05), and
230 mothers with postpartum COVID-19 (57.2% vs. 1.5%, p≤0.0001). Of the 173 infants with
231 medically attended COVID-19 episodes, 27 (15.6%) were diagnosed at <1 month of age, 29
232 (16.7%) at 1 month of age, 28 (16.2%) at 2 months, 16 (9.2%) at 3 months, 31 (17.9%) at 4 months,
233 and 42 (24.3%) at 5 months of age. A larger proportion of infants with medically attended COVID-
234 19 episodes also had any underlying medical condition (12.1% vs. 7.3%, p=0.02). Six of 173
235 infants with medically attended COVID-19 (3.5%) had an underlying heart-related condition, 11
236 (6.4%) had an underlying lung-related condition, and 1 (0.6%) had a liver-related condition
237 (Appendix A); all conditions were documented prior to or on the same days as the infant's COVID-
238 19 diagnosis or positive SARS-CoV-2 test result.

239 Among the 173 infants with medically attended COVID-19 episodes, 148 (85.6%) were
240 first diagnosed in association with telemedicine visits, 20 (11.6%) during ambulatory/outpatient
241 visits, one (0.6%) during an emergency room visit, and four (2.3%) during hospitalization (data

242 not shown). All four hospitalizations occurred among infants aged 0-1 month. Hospital lengths of
243 stay ranged from 2-5 days, and none included intensive care unit admission, mechanical
244 ventilation, or extracorporeal membrane oxygenation.

245

246 *Incidence of Medically Attended COVID-19 Episodes*

247 The overall cumulative incidence of medically attended COVID-19 episodes was 0.95%.

248 The aggregate crude incidence rate among the full cohort was 0.6 per 1,000 person-weeks. Site-

249 adjusted incidence rates of medically attended COVID-19 episodes varied by local SARS-CoV-2

250 COVID-19 circulation (high versus low), infant age, maternal race/ethnicity, maternal Medicaid

251 status, infant underlying conditions, and maternal COVID-19 diagnosis (Table 2). The overall site-

252 adjusted incidence rates of medically attended COVID-19 episodes were 0.6 per 1,000 person-

253 weeks during high SARS-CoV-2 circulation periods and 0.4 per 1,000 person-weeks during low

254 circulation periods. By infant age, the site-adjusted incidence rates of medically attended COVID-

255 19 episode were highest among infants under 1 month and 1 month of age (2.0 and 2.0 per 1,000

256 person-weeks, respectively) compared with older infants.

257 Infants born to mothers with COVID-19 diagnosed during the six-month postpartum period

258 had a higher incidence rate of medically attended COVID-19 episodes (12.5 per 1,000 person-

259 weeks) than infants born to mothers diagnosed with COVID-19 during pregnancy alone (0.5 per

260 1,000 person-weeks) and compared to infants born to mothers who were never diagnosed with

261 COVID-19 during pregnancy or the postpartum period (0.2 per 1,000 person-weeks).

262

263 DISCUSSION

264 Among a cohort of >18,000 infants born during the first year of the COVID-19 pandemic
265 in the United States and followed up to six months of age, the overall cumulative incidence of
266 medically attended COVID-19 episodes was 0.95%. Incidence rates varied by level of community
267 transmission, maternal COVID-19 status, maternal race/ethnicity, and infant month of age. The
268 majority of medically attended COVID-19 episodes were outpatient encounters, largely
269 comprising telemedicine visits, and only four infants (<0.1% of the cohort) during their first month
270 of life had COVID-19 associated hospitalizations. Findings from this analysis provide reassurance
271 that the overall risk of medically attended COVID-19 episodes among young infants was low
272 during the study period, which preceded the emergence of both the Delta and Omicron variants,
273 and risk of COVID-19-associated hospitalizations was very low for this group. Incidence rates of
274 medically attended COVID-19 episodes were higher among infants of women with COVID-19
275 diagnosed during the six-month postpartum period compared to infants born to mothers diagnosed
276 at other times or never diagnosed suggesting potential horizontal transmission between mother and
277 infant and increasing opportunities for community acquisition with increasing infant age. This
278 finding underscores the importance of COVID-19 prevention measures for household members
279 and caregivers of young infants to reduce transmission to young infants. In addition, the highest
280 incidence rates of medically attended COVID-19 episodes were among infants born to Hispanic
281 (0.9 per 1,000 person-weeks) and Non-Hispanic Black mothers (0.9 per 1,000 person-weeks) after
282 adjusting for study site, a finding consistent with those from other studies documenting disparities
283 related to COVID-19 disease burden among minority populations during this study period.^{8,9,10,11}

284 Findings from this analysis suggest that the risk of medically attended COVID-19 episodes
285 among infants in the United States was low during the first year of the pandemic. We were not
286 able to assess the influence of community exposures or preventive practices on incidence rate of

287 medically attended COVID-19 episodes among young infants. However, our finding that incidence
288 rates of medically attended COVID-19 episodes were higher among infants of mothers diagnosed
289 with COVID-19 during the six-month postpartum period suggest that SARS-CoV-2 transmission
290 within households and from caregivers may be important sources of infection for young infants.
291 To reduce the risk of SARS-CoV-2 infection and subsequent medically attended COVID-19
292 episodes among infants, infection prevention counseling for families and caregivers of young
293 infants should include information about the importance of non-pharmaceutical prevention
294 measures such as handwashing and mask wearing and the benefits of COVID-19 vaccination
295 among eligible persons. Maternal COVID-19 vaccination (either during or prior to pregnancy)
296 may decrease SARS-CoV-2 infection among infants by passive transfer of maternal antibodies to
297 infants and by preventing maternal infections during the postpartum period.^{12,13,14,15} Maternal
298 vaccination during pregnancy has an estimated 61% effectiveness against COVID-19
299 hospitalization in infants aged <6 months and maternal COVID-19 vaccination is recommended
300 by both CDC and the American College of Obstetricians and Gynecologists (ACOG).^{16,17,18} Other
301 family members and caregivers should also be encouraged to receive COVID-19 vaccine to reduce
302 their risk of SARS-CoV-2 infection and subsequent transmission to young infants in their care.

303 Infants with medically attended COVID-19 episodes had more underlying medical
304 conditions diagnosed during the first six months of life compared with infants without COVID-
305 19, though this difference was small. This finding is consistent with the literature that found
306 younger children with severe disease were more likely to have underlying conditions.^{5,19} This may
307 be due to increased healthcare seeking behaviors among individuals with medical conditions that
308 afford more opportunities to get SARS-CoV-2 testing.²⁰

309 This analysis has several limitations. First, medically attended COVID-19 episodes were
310 identified based on clinician-initiated testing and/or ICD-10 codes for COVID-19 which may have
311 led to under-ascertainment of episodes and/or differential detection of episodes among infants with
312 different demographic or maternal characteristics. For example, infants of women with COVID-
313 19 diagnosed during the postpartum period may have been more likely to be tested for SARS-
314 CoV-2 because they had a known history of exposure to someone with COVID-19. Second, this
315 analysis was based on data from the first year of the COVID-19 pandemic in the United States and
316 may not be fully generalizable to subsequent periods of SARS-CoV-2 circulation of emerging
317 variants during which younger pediatric age groups were increasingly impacted. Third, this
318 analysis was not able to assess factors that may have led to differences in incidence rates of
319 medically attended COVID-19 episodes by site, such as differences in SARS-CoV-2 circulation
320 patterns, clinical testing practices, and demographic characteristics of the source population.
321 Lastly, the analysis did not account for maternal COVID-19 vaccination status. However, the
322 frequency of women fully vaccinated in this cohort was likely low since women in this cohort
323 were pregnant prior to April 2021 when COVID-19 vaccine became available to the general
324 population of adults <65 years of age in the United States.^{21,22}

325

326 CONCLUSIONS

327 Among a cohort of infants aged <6 months at three sites in the US during the first year of
328 the COVID-19 pandemic, the incidence of medically attended COVID-19 episodes was low with
329 outpatient care encounters accounting for the large majority of episodes. The highest incidence
330 rates of medically attended COVID-19 episodes occurred among infants in the first two months of
331 life and among infants of women diagnosed with COVID-19 during the postpartum period. These

332 findings underscore the importance of COVID-19 prevention measures for pregnant women,
333 household members, and families and caregivers of infants to protect infants who are too young to
334 receive COVID-19 vaccine.

Acknowledgements

We express our gratitude to the Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network: Electronic Cohort (eESPI) team for their tremendous effort in abstracting electronic health record data. The authors at KPNC thank Andrew K. Hirst for his help with programming and technical support, the authors at KPNW acknowledge Elizabeth Shuster and Jan Van Marter. The authors at Baylor College of Medicine acknowledge Nanette Bond and Patricia Santarcangelo. The authors at Abt Associates acknowledge Michael Duckworth and Peiyi Zhang. The authors from CDC acknowledge Michael Daugherty and Kellye Sliger for data management.

References

1. Dong Y, Mo X, Hu Y, et al. Epidemiology of COVID-19 Among Children in China. *Pediatrics*. 2020;145(6):e20200702. doi:10.1542/peds.2020-0702
2. Liu X, Tang J, Xie R, et al. Clinical and Epidemiological Features of 46 Children <1 Year Old With Coronavirus Disease 2019 in Wuhan, China: A Descriptive Study [published correction appears in *J Infect Dis*. 2021 Feb 13;223(3):540]. *J Infect Dis*. 2020;222(8):1293-1297. doi:10.1093/infdis/jiaa472
3. Ouldali N, Yang D, Madhi F, et al. Factors Associated With Severe SARS-CoV-2 Infection. *Pediatrics*. 2021;147(3):e2020023432. doi:10.1542/peds.2020-023432
4. Neef V, Buxmann H, Rabenau H, Zacharowski K, Raimann F. Characterization of neonates born to mothers with SARS-CoV-2 infection: Review and meta-analysis. *Pediatr Neonatol*. 2021;62(1):11-20. doi:10.1016/j.pedneo.2020.10.001.
5. Hobbs CV, Woodworth K, Young CC, et al. Frequency, Characteristics and Complications of COVID-19 in Hospitalized Infants. *Pediatr Infect Dis J*. 2022;41(3):e81-e86. doi:10.1097/INF.0000000000003435
6. Woodruff RC, Campbell AP, Taylor CA, et al. Risk Factors for Severe COVID-19 in Children [published online ahead of print, 2021 Dec 22]. *Pediatrics*. 2021;e2021053418. doi:10.1542/peds.2021-053418
7. Health and Human Services. Number of COVID-19 cases confirmed by U.S. county & State Health Departments by Report Week. Protect Public Data Hub 2021 [cited 2021 April 8]; Available from: www.protect.hhs.gov.
8. Acosta AM, Garg S, Pham H, et al. Racial and Ethnic Disparities in Rates of COVID-19-Associated Hospitalization, Intensive Care Unit Admission, and In-Hospital Death in the United States From March 2020 to February 2021. *JAMA Netw Open*. 2021;4(10):e2130479. Published 2021 Oct 1. doi:10.1001/jamanetworkopen.2021.30479
9. Centers for Disease Control and Prevention. COVID-19: Risk for COVID-19 Infection, Hospitalization, and Death by Race/Ethnicity. 2022 Feb 1 [cited 2022 March 9]; Available from: <https://www.cdc.gov/coronavirus/2019-ncov/covid-data/investigations-discovery/hospitalization-death-by-race-ethnicity.html>
10. Jacobson M, Chang TY, Shah M, Pramanik R, Shah SB. Racial and Ethnic Disparities in SARS-CoV-2 Testing and COVID-19 Outcomes in a Medicaid Managed Care Cohort. *Am J Prev Med*. 2021;61(5):644-651. doi:10.1016/j.amepre.2021.05.015
11. Yehia BR, Winegar A, Fogel R, et al. Association of Race With Mortality Among Patients Hospitalized With Coronavirus Disease 2019 (COVID-19) at 92 US

- Hospitals. *JAMA Netw Open*. 2020;3(8):e2018039. Published 2020 Aug 3.
doi:10.1001/jamanetworkopen.2020.18039
12. Rottenstreich A, Zarbiv G, Oiknine-Djian E, Zigran R, Wolf DG, Porat S. Efficient Maternofetal Transplacental Transfer of Anti- Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Spike Antibodies After Antenatal SARS-CoV-2 BNT162b2 Messenger RNA Vaccination. *Clin Infect Dis*. 2021;73(10):1909-1912. doi:10.1093/cid/ciab266
 13. Beharier O, Plitman Mayo R, Raz T, et al. Efficient maternal to neonatal transfer of antibodies against SARS-CoV-2 and BNT162b2 mRNA COVID-19 vaccine [published correction appears in *J Clin Invest*. 2021 Oct 1;131(19):]. *J Clin Invest*. 2021;131(13):e150319. doi:10.1172/JCI150319
 14. Collier AY, McMahan K, Yu J, et al. Immunogenicity of COVID-19 mRNA Vaccines in Pregnant and Lactating Women. *JAMA*. 2021;325(23):2370-2380. doi:10.1001/jama.2021.7563
 15. Mithal LB, Otero S, Shanes ED, Goldstein JA, Miller ES. Cord blood antibodies following maternal coronavirus disease 2019 vaccination during pregnancy. *Am J Obstet Gynecol*. 2021;225(2):192-194. doi:10.1016/j.ajog.2021.03.035
 16. Halasa NB, Olson SM, Staat MA, et al. Effectiveness of Maternal Vaccination with mRNA COVID-19 Vaccine During Pregnancy Against COVID-19-Associated Hospitalization in Infants Aged <6 Months - 17 States, July 2021-January 2022. *MMWR Morb Mortal Wkly Rep*. 2022;71(7):264-270. Published 2022 Feb 18. doi:10.15585/mmwr.mm7107e3.
 17. Centers for Disease Control and Prevention (CDC). National Center for Immunization and Respiratory Diseases (NCIRD), Division of Viral Diseases. COVID-19 Vaccines While Pregnant or Breastfeeding. December 6, 2021. Retrieved from: <https://www.cdc.gov/coronavirus/2019-ncov/vaccines/recommendations/pregnancy.html> on December 16, 2021.
 18. The American College of Obstetrics and Gynecologists. Practice Advisory: COVID-19 Vaccination Considerations for Obstetric–Gynecologic Care. 2021 Dec 3. [Cited: Dec 16 2021]. Retrieved from: <https://www.acog.org/clinical/clinical-guidance/practice-advisory/articles/2020/12/covid-19-vaccination-considerations-for-obstetric-gynecologic-care> on December 16, 2021.
 19. Kim L, Whitaker M, O'Halloran A, et al. Hospitalization Rates and Characteristics of Children Aged <18 Years Hospitalized with Laboratory-Confirmed COVID-19 - COVID-NET, 14 States, March 1-July 25, 2020. *MMWR Morb Mortal Wkly Rep*. 2020;69(32):1081-1088. Published 2020 Aug 14. doi:10.15585/mmwr.mm6932e3
 20. Lu P, Kong D, Shelley M. Risk Perception, Preventive Behavior, and Medical Care Avoidance among American Older Adults During the COVID-19 Pandemic. *J Aging Health*. 2021;33(7-8):577-584. doi:10.1177/08982643211002084
 21. COVID Data Tracker: COVID-19 vaccination among pregnant people aged 18-49 years overall, by race/ethnicity, and date reported to CDC - Vaccine Safety Datalink, United States. Centers for Disease Control and Prevention. Retrieved from: <https://covid.cdc.gov/covid-data-tracker/#vaccinations-pregnant-women> on January 11, 2022.
 22. Razzaghi H, Meghani M, Pingali C, et al. COVID-19 Vaccination Coverage Among Pregnant Women During Pregnancy - Eight Integrated Health Care Organizations, United

States, December 14, 2020-May 8, 2021. *MMWR Morb Mortal Wkly Rep.* 2021;70(24):895-899. Published 2021 Jun 18. doi:10.15585/mmwr.mm7024e2

Table 1. Maternal and Infant Characteristics by whether Infants had Medically Attended Coronavirus Disease (COVID-19) Episodes before 6 Months of Age, Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network: Electronic Cohort (eESPI) (N= 18,192 infants).

	Total (N= 18,192) <i>n</i>	Infants with Medically Attended COVID-19 Episodes (n=173) <i>n (row %)</i>	Infants without Medically Attended COVID-19 Episodes (n=18,019) <i>n (row %)</i>	<i>P</i> ^a
<i>Characteristics</i>				
<i>Study Site</i>				<0.0001
A	4794	38 (0.8)	4756 (99.2)	
B	7434	106 (1.4)	7328 (98.6)	
C	5964	29 (0.5)	5935 (99.5)	
<i>Infant Sex</i>				0.66
Male	9345	93 (1.0)	9252 (99.0)	
Female	8842	80 (0.9)	8762 (99.1)	
Unknown	5	0 (0.0)	5 (100)	
<i>Maternal Race/Ethnicity</i> ^b				<0.0001

Non-Hispanic White	7583	32 (0.4)	7551 (99.6)	
Non-Hispanic Black	1871	25 (1.3)	1846 (98.7)	
Hispanic	5112	81 (1.6)	5031 (98.4)	
Other	3318	30 (0.9)	3288 (99.1)	
Unknown	308	5 (1.6)	303 (98.4)	
<i>Maternal Medicaid</i>				0.05
Yes	4085	51 (1.2)	4034 (98.8)	
No	13947	120 (0.9)	13827 (99.1)	
Unknown	160	2 (1.2)	158 (98.8)	
<i>Maternal COVID-19</i>				<0.0001
<i>Diagnosis^c</i>				
No Known COVID-19	17122	66 (0.4)	17056 (99.6)	
During Pregnancy only	623	6 (1.0)	617 (99.0)	
During Post-partum	367	99 (27.0)	268 (73.0)	
Period				
During Pregnancy and	80	2 (2.5)	78 (97.5)	
Post-partum Period				
<i>Gestational Age at Birth^d</i>				0.31
Preterm (< 37 weeks)	1819	18 (1.0)	1801 (99.0)	
Term or Post-Term (≥ 37	16373	155 (1.0)	16218 (99.0)	
weeks)				
<i>Any Underlying Medical Conditions</i>				
Infant ^e				

Yes	1327	21 (1.6)	1306 (98.4)	0.02
No	16865	152 (0.9)	16713 (99.1)	
Maternal^e				
Yes	10320	91 (0.9)	10229 (99.1)	0.001
No	7872	82 (1.0)	7790 (99.0)	

^a Unadjusted chi-square and fisher's exact test p-values of ≤ 0.05 were considered statistically significant.

^b Race/Ethnicity was extracted from medical records.

^c Maternal COVID-19 diagnosis was based on a recorded COVID-19 diagnosis (ICD-10: U07.1) or a recorded visit with confirmed SARS-CoV-2 infection by any method (RT-PCR, antigen, etc.) based on hospital records at any time during the pregnancy or during the six months after delivery.

^d Gestational age at delivery (preterm [<37 weeks], term [$37-42$ weeks], or post-term [>42 weeks]) was determined using reported gestational age at delivery or derived based on delivery date and estimated date of conception.

^e Definition of any underlying medical conditions for mothers and infants can be found in Appendix.

Table 2. Incidence rates^a per 1,000 person-weeks of medically attended COVID-19 episodes among infants under 6 months of age born to mothers in the eESPI cohort, Epidemiology of SARS-CoV-2 in Pregnancy and Infancy (ESPI) Network: Electronic Cohort (eESPI) (N=173).

	Infants with Medically Attended COVID-19 Episodes	Person-Weeks ^b	Incidence Rates per 1,000 Person-Weeks, 95% CI
<i>Characteristics</i>			
<i>Overall incidence rate</i>	173	307059.86	0.6 (0.5 – 0.6)
<i>SARS-CoV-2 Circulation^c</i>			
Low	90	188198.86	0.4 (0.3 – 0.5)
High	83	111843.71	0.6 (0.5 – 0.8)
<i>Infant Age^d</i>			
Under 1 month	27	67648.00	2.0 (1.7 – 2.5)
1 month	29	58250.57	2.0 (1.6 – 2.4)
2 months	28	50772.86	1.6 (1.3 – 2.1)
3 months	16	45530.00	1.3 (0.9 – 1.8)
4 months	31	40628.14	1.2 (0.8 – 1.7)
5 months	42	36421.71	0.7 (0.4 – 1.2)
<i>Infant Sex</i>			

Male	93	158088.57	0.5 (0.4 – 0.6)
Female	80	148922.00	0.5 (0.4 – 0.6)
<i>Maternal Race/Ethnicity^e</i>			
Non-Hispanic White	32	129786.29	0.2 (0.1 – 0.3)
Non-Hispanic Black	25	28971.43	0.9 (0.6 – 1.4)
Hispanic	81	82956.29	0.9 (0.7 – 1.1)
Other	30	59839.57	0.3 (0.2 – 0.5)
Unknown	5	5506.29	0.6 (0.3 – 1.5)
<i>Maternal Medicaid</i>			
Yes	51	64885.86	0.8 (0.6 – 1.1)
No	120	239298.14	0.4 (0.3 – 0.5)
Unknown	2	2875.86	0.6 (0.1 – 2.2)
<i>Maternal COVID-19</i>			
<i>Diagnosis^f</i>			
During Pregnancy only	6	6761.43	0.5 (0.2 – 1.5)
		7412.00	
During Post-partum Period	99	1187.57	12.5 (9.8 – 16.0)
		291698.86	
During Pregnancy and Post-partum Period	2		1.6 (0.4 – 6.3)
No known COVID-19	66		0.2 (0.2 – 0.3)

Any Underlying Medical

Conditions

Infant^g

Yes	21	24417.29	0.7 (0.4 – 1.1)
No	152	282642.57	0.5 (0.4 – 0.6)

Maternal^h

Yes	91	174994.14	0.5 (0.4 – 0.6)
No	82	132065.71	0.5 (0.4 – 0.6)

^a Overall incidence rate is a crude aggregate incidence rate. Incidence rates by circulation period and infant and maternal characteristics are site-adjusted.

^b Person-week for all infants <6 months of age born to mothers in the eESPI cohort.

^c High and low SARS-CoV-2 circulation weeks were defined for each site as weeks with case counts above the median case count (high) or below the median case count (low) for the study period, using Health and Human Services (HHS) representative county-level surveillance data for Texas (Harris County), Oregon (Multnomah County), and California (Santa Clara County) in each health system’s service area (HHS 2021).

^d Infant age was defined as 0-30 days (< 1 month old); 31-60 days (1 month); 61-90 days (2 months); 91-120 days (3 months); 121-150 (4 months); 151-185 days (5 months).

^e Race/Ethnicity was extracted from medical records.

^f Medically attended maternal COVID-19 was based on a recorded COVID-19 diagnosis (ICD-10: U07.1) or a recorded visit with confirmed SARS-CoV-2 by any method (RT-PCR, antigen, etc.) based on hospital records at any time during the pregnancy or during the six months after delivery.

^g Infant age was defined as 0-30 days (< 1 month old); 31-60 days (1 month); 61-90 days (2 months); 91-120 days (3 months); 121-150 (4 months); 151-185 days (5 months).

^h Medically attended maternal COVID-19 was based on a recorded COVID-19 diagnosis (ICD-10: U07.1) or a recorded visit with confirmed SARS-CoV-2 by any method (RT-PCR, antigen, etc.) based on hospital records at any time during the pregnancy or during the six months after delivery.

Appendix A: Data Dictionary

Variable	ESPI Variable	Variable Description	ICD-10 Codes
Medically Attended Infant COVID-19	IN_COVID_CONF_VTST# OR IN_ARFI_COVID	Confirmed SARS-CoV-2 by any method for any test for neonate OR Identifies COVID-19 diagnosis code	ICD-10: U07.1
Medically Attended Maternal COVID-19 during Pregnancy	PR_COVID_CONF_VTST# OR PR_ARFI_COVID	Confirmed SARS-CoV-2 by any method for any test during pregnancy OR Identifies COVID-19 diagnosis code during pregnancy	ICD-10: U07.1
Medically Attended Maternal COVID-19 post-partum	PP_COVID_CONF_VTST# OR PP_ARFI_COVID	Confirmed SARS-CoV-2 by any method for any test OR Identifies COVID-19 diagnosis code post-partum	ICD-10: U07.1
Maternal Race/Ethnicity	Calculated based on responses to PR_MAT_ETHNICITY AND PR_MAT_RACE	Maternal race and Maternal ethnicity	No codes
Maternal Medicaid	PR_MAT_MEDICAID	Maternal status for Medicaid coverage	No codes
Gestational Age	PR_PREG_GA_DEL_NEO# or if blank calculated based on	Gestational age at delivery date	ESPI derived from DELIVERY_DT_NEO#, FIRST_US_DT, GA_FIRST_US
	PR_DELIVERY_DT_NEO	Date of delivery/End of Pregnancy	This should be considered as End of Pregnancy date, ie, if the pregnancy ends in a way other than a delivery (eg, miscarriage, abortion), the date of that outcome should be recorded under this variable.
	PR_EST_CONCEPTION	Estimated date of conception	ESPI calculated from EST_DELIVERY: EST_CONCEPTION = (EST_DELIVERY – 280)

Infant Underlying Conditions	IN_HR_CONDITION_PL	High risk medical condition (chronic condition, not pregnancy complication)	See appendix B.
Maternal Underlying Conditions	PR_HR_CONDITION_PL	High risk medical condition (chronic condition, not pregnancy complication)	See appendix B.
Timing of Maternal COVID-19	IF PR_COVID_CONF_VTST# OR PR_ARFI_COVID then COVID during pregnancy.		ICD-10: U07.1
	IF PP_COVID_CONF_VTST# OR PP_ARFI_COVID then COVID-19 during post-partum.		ICD-10: U07.1
Infant Hospitalization	IN_HOSP_ADM_DT	Hospital admission date	
Infant Death	INF_DEATH	Infant Death	
Live Birth	Calculated based on responses to PR_OUT_STILLBIRTH_NEO#	Stillborn infant (infant born >=20 weeks gestation with no sign of life) [multiple fetuses/neonates]	O60.1; O60.10; O60.12; O60.13; O60.14; P07.21; P07.22; P07.23; P07.24; P07.25; P07.26; P07.3; P07.30; P07.31; P07.32; P07.33; P07.34; P07.35; P07.36; P07.37; P07.38; P07.39
	PR_PREG_GA_DEL_NEO#/ PREG_GA_DEL_EX_NEO/ PREG_GA_DEL_ANALYTIC_NEO#	Gestational age at delivery date	Derived or extracted from Medical Records. For Baylor: PREG_GA_DEL_ANALYTIC_NEO# = PREG_GA_DEL_EX_NEO# For KPNW and KPNC: PREG_GA_DEL_ANALYTIC_NEO# = PREG_GA_DEL_NEO#
	PR_OUT_ABORTION_NEO	Induced termination of pregnancy	Z33.2, O04.80.
	PR_OUT_PRETERM_NEO	Preterm birth (A live birth with an estimated gestation <37 weeks) [multiple fetuses/neonates]	O60.1; O60.10; O60.12; O60.13; O60.14; P07.21; P07.22; P07.23; P07.24; P07.25; P07.26; P07.3; P07.30; P07.31; P07.32; P07.33; P07.34; P07.35;

			P07.36; P07.37; P07.38; P07.39
	OUT_LIVEBIRTH_NEO	Live birth	
	PR_OUT_MISCARRIAGE_NEO		
Infant Heart *NAC = Non-Acute; AC = Acute	IN_HR_AC_HEART_FAIL_VL	(Acute or chronic) heart failure diagnosis	ICD-10: I50.21, I50.23, I50.31, I50.33, I50.41, I50.43
	IN_HR_AC_HEART_VL	Acute heart disease diagnosis	ICD-10: I40, J10.82, J11.82, I30, I31.4, R57.0, I50.21, I50.23, I50.31, I50.33, I50.41, I50.43, I50.811, I50.813, I16, I10, I11, I11.9, I11.0, I15, I15.0, I15.9, I16.0, I16.1, I16.9, I20.0, I21, I21.0, I21.1, I21.2, I21.3, I21.4, I21.9, I22, I22.0, I22.1, I22.2, I22.8, I22.9, I24
	IN_HR_CARD_ARRST_VL	Cardiac arrest diagnosis	ICD-10: I46.9
	IN_HR_HEART_FAIL_VL	(Acute or chronic) heart failure diagnosis	ICD-10: I50
	IN_HR_NAC_HEART_VL	Non-acute heart disease diagnosis	ICD-10: A52.0, H35.031-039, I01, I09.2, I05-08, I34, I35, I36, I37, I09, I12, I13, I23, I25-28, I33, I31 (except I31.4), I38, I39, I42-44, I46, I47, I48, I49, I50.1, I50.9, I41, I51, I52, I70, I71, I72, I73, I74, I75, M30.0, M31, I77, I79, I97.0, I97.1, Q21-27, T82, Z95, Q20, Q27.0, Q27.3, Q27.4, Q27.8, Q27.9, Q28, Q89.3, R00.1, Z98.61, Z79.82
Infant Liver *NAC = Non-Acute; AC = Acute	IN_HR_LIVER_VL	(Acute or chronic) Liver disease diagnosis	ICD-10: K70, K73, K74, K75.1-K75.9, I85, K71, K72, K75, K76, K77
	IN_HR_NAC_LIVER_FAIL_VL	(Non-acute) liver failure diagnosis	ICD-10: K72.1, K76.2
	IN_HR_AC_LIVER_FAIL_VL	Acute liver failure diagnosis	ICD-10: K72.0, K76.3
Infant Lung	IN_HR_OLUNG_VL	Lung disease diagnosis, not asthma	ICD-10: A15, A17, A18, A19, A31, D86, E84, J40, J41, J42, J43, J47, J60, J61, J62.0, J62.8, J63.6, J64, J67, J68, J69.0, J69.1, J69.8, J70.9,

			J85, J93, J98, M34, M35, Q34, R09.1, A31.0, B39, B40., B41, B44, B45, B46.0, D86.0, E88.01, J62, J63, J65, J66, J69, J70, J82, J84, J86, J95.0, J96, J98.1, J99, P25, P26, P27, P28, Q33, T86.8, J44
--	--	--	--

Appendix B: List of High-Risk Medical Conditions

This set of variables looks at whether each participant had different high-risk medical conditions in diagnosis codes across every visit or admission within the time window for the pull. Each visit or admission for the participant will be evaluated for whether it included one of the listed ICD-10 codes. If any visit/admission for the participant across the entire time window did include one of the ICD-10 codes in question, the variable will be equal to 1 (One or more codes listed). If not, the variable will be equal to 0 (No code listed).

ESPI Variable	Variable Description	ICD-19 Codes
IN_HR_EXCLD_ANEMIA_PL ^a	High risk medical condition (chronic condition, not pregnancy complication) for Infant excluding Anemia	Presence of any of the conditions listed below.
PR_HR_EXCLD_ANEMIA_PL ^b	High risk medical condition (chronic condition, not pregnancy complication) for Mother during pregnancy excluding Anemia	Presence of any of the conditions listed below.
HR_BLOOD_PL	Blood disorder diagnosis	ICD-10: D50.0, D50.8, D50.9, D51, D52, D53, D55-61, D64.0-3, D63.1, D63.0, D63.8, D64.4, D64.8, D64.81, D64.89, D64.9, D66-75, D77

HR_BLOOD_EXCLD_ANEMIA_PL	Blood disorder diagnosis (other than anemia)	ICD-10: D56-61, D64.0-4, D64.8, D63.1, D63.0, D63.8, D64.81, D66-75, D77
HR_DIABT_PL	Diabetes diagnosis	ICD-10: E08-E11
HR_AC_HEART_FAIL_PL	Acute heart failure diagnosis	ICD-10: I50.21, I50.23, I50.31, I50.33, I50.41, I50.43
HR_HEART_FAIL_PL	(Acute or chronic) heart failure diagnosis	ICD-10: I50
HR_CARD_ARRST_PL	Cardiac arrest diagnosis	ICD-10: I46.9
HR_AC_HEART_PL	Acute heart disease diagnosis	ICD-10: I40, J10.82, J11.82, I30, I31.4, R57.0, I50.21, I50.23, I50.31, I50.33, I50.41, I50.43, I50.811, I50.813, I16, I10, I11, I11.9, I11.0, I15, I15.0, I15.9, I16.0, I16.1, I16.9, I20.0, I21, I21.0, I21.1, I21.2, I21.3, I21.4, I21.9, I22, I22.0, I22.1, I22.2, I22.8, I22.9, I24
HR_NAC_HEART_PL	Non-acute heart disease diagnosis	ICD-10: A52.0, H35.031-039, I01, I09.2, I05-08, I34, I35, I36, I37, I09, I12, I13, I23, I25-28, I33, I31 (except I31.4), I38, I39, I42-44, I46, I47, I48, I49, I50.1, I50.9, I41, I51, I52, I70, I71, I72, I73, I74, I75, M30.0, M31, I77, I79, I97.0, I97.1, Q21-27, T82, Z95, Q20, Q27.0, Q27.3, Q27.4, Q27.8, Q27.9, Q28, Q89.3, R00.1, Z98.61, Z79.82
HR_CANCER_PL	Cancer diagnosis	ICD-10: C00, C01, C02, C07, C08, C03, C04, C05, C06, C09, C10, C11, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C48, C26, C30, C31, C32, C33, C34, C38, C37, C39, C40, C41, C44, C49, C43, C50, C46, C55, C53, C58, C54, C56, C51, C52, C61, C62, C60, C67, C64, C69, C71, C72, C73, C74, C75, C76, C77, C78, C79, C80, C81, C83, C90, C91, C92, C93, C94, C95, C7A, D02, D37-44, D48, Z51.11, Z51.12, C47, C4A, C57, C65, C66, C68, C70, C7B, D03, Z85, M36.0, Z51.0, Z51.1, C95.00, C95.10, D61.0, D61.2, C82, C84, C85, C86, C88, C96
HR_IMMUNE_PL	Immune disorder diagnosis	ICD-10: B20, B33.3, B59, D73, G70.8, M32.10, M35, M05, M06, R82.8, R84.7, R85.7, R87.7, R89.7, T45, Z21, Z94, B97.3, D47.Z1, D76, M07, M35.0, M35.9, Q89.0, T45.1X1, T86.1, T86.2, T86.3, T86.4, T86.81, T86.85, Z48.2, Z94.0, Z94.1, Z94.2, Z94.3, Z94.4, Z94.82, Z94.83, Z94.84, T86.0, T86.5, D80, D81, D82, D83, D84, D89, D89.81, M08, L40, M32, M30, M33, D46, Z79.5, Z79.52, B97.35, O98.7, D61.9, D73.0
HR_AC_RENAL_FAIL_PL	Acute renal failure diagnosis	ICD-10: N17, N01
HR_NAC_RENAL_FAIL_PL	(Non-acute) Renal failure diagnosis	ICD-10: I13.11, I13.2, K76.7, D63.1, I12.0, I13.11, I13.2, N03, N04, N18, N19, N26.9, N25.0, N25.1, N27.0, N27.1, N27.9, N28.89, Q61, Z49, Z91.15, N02, N06, N07, N08, N11, N14, N15, N16, N25, N26, N28, Q27.1, Q27.2, Q60, Z99.2

HR_AC_LIVER_FAIL_PL	Acute liver failure diagnosis	ICD-10: K72.0, K76.3
HR_NAC_LIVER_FAIL_PL	(Non-acute) liver failure diagnosis	ICD-10: K72.1, K76.2
HR_LIVER_PL	(Acute or chronic) Liver disease diagnosis	ICD-10: K70, K73, K74, K75.1-K75.9, I85, K71, K72, K75, K76, K77
HR_ASTHMA_PL	Asthma diagnosis	ICD-10: J45
HR_OLUNG_PL	Lung disease diagnosis, not asthma	ICD-10: A15, A17, A18, A19, A31, D86, E84, J40, J41, J42, J43, J47, J60, J61, J62.0, J62.8, J63.6, J64, J67, J68, J69.0, J69.1, J69.8, J70.9, J85, J93, J98, M34, M35, Q34, R09.1, A31.0, B39, B40., B41, B44, B45, B46.0, D86.0, E88.01, J62, J63, J65, J66, J69, J70, J82, J84, J86, J95.0, J96, J98.1, J99, P25, P26, P27, P28, Q33, T86.8, J44
HR_OBESE_PL	Obesity diagnosis	ICD-10: E66, O99.210-215, O99.840-845, Z68.4
HR_SEV_OBESE_PL	Severe (morbid) obesity dx	ICD-10: E66.01
HR_OMETBOL_PL	Metabolic disorder diagnosis not obesity	ICD-10: E03-E07, E22, E23, E32, E27, E40-E46, E50-E56, E70-E72, E74, E78, E88, M10, E83, E75.2, E76, E77, E79, E80, E85, E89.1, E89.6, E01, E20, E21, E24, E25, E26, E28, E31, E34
HR_ALT_MENT_PL	Altered mental status diagnosis	ICD-10: F05, F06.0, F06.1, F06.2, F06.30, F06.4, F06.8, G45.4, R40.0, R40.4, R41.82, R44.0, R41
HR_ENCEPHAL_PL	Encephalopathy diagnosis	ICD-10: G93.4, I67.4, K72.90, K72.91
HR_MENINGITIS_PL	Meningitis diagnosis	ICD-10: A02.21, A17.0, A39, A87.0, A87.1, B37.5, B38.4, G00, G01, G02, G03
HR_ANOX_BRN_DMG_PL	Anoxic brain damage diagnosis	ICD-10: G93.1
HR_ENCEPH_MYEL_PL	Encephalitis or myelitis diagnosis	ICD-10: A39.81, G05, G37.3
HR_COMA_PL	Coma diagnosis	ICD-10: R40.20, R40.3
HR_POLYNEURO_PL	Critical illness polyneuropathy diagnosis	ICD-10: G62.81
HR_CEREBRAL_INFARC_PL	Cerebral infarction diagnosis	ICD-10: G43.6, I63.019, I63.119, I63.139, I63.20, I63.219, I63.22, I63.239, I63.30, I63.40, I63.50, I63.59
HR_CEREBRAL_HEMR_PL	Cerebral hemorrhage diagnosis	ICD-10: I60.9, I61.9, I62
HR_CEREBRAL_EDEMA_PL	Cerebral edema diagnosis	ICD-10: G93.6
HR_NEURO_PL	Acute or Chronic Neurologic disease diagnosis	ICD-10: A17, A81, B90.0, F01, F02, F03, F07, F71, F72, F73, E75, G20, G25, G26, G11, M47, G60, G35, G36, G81, G80, G82, G40, G93, G96, I02, I60, I61, I62, I65, I66, I67.82, I67.9, I69, G71.13, R56, T85, I68, A17.0, E75.02, E75.19, E75.4, F84.2, G10, G12-14, G21, G23, G24, G30, G31, G32, G37, G45, G46, G63, G64, G70, G71, G73, G83, G90.3, G91, G94, G95, G99.2,

		H49.81, Q05, Q76-79, Q85, Q87.4, Q90-93, Q96, R41, R53.2, R54
HR_AC_NEURO_PL	Only Acute Neurologic disease diagnosis	ICD-10: G04.0, I63, I67.81, I67.82, G45, G45.4, G36, G04, G05, G61.0, I60-I62, G00-G03
HR_ART_VEN_EMBOL_PL	Arterial or venous embolism diagnosis	ICD-10: I74, I76, I82
HR_AC_ENDOCRINE_PL	Acute endocrine complications	ICD-10: E08.1, E08.10, E08.11, E09.1, E09.10, E09.11, E10.1, E10.10, E10.11, E11.1, E11.10, E11.11, E13.1, E13.10, E13.11, E08.0, E08.00, E08.01, E09.0, E09.00, E09.01, E11.0, E11.00, E11.01, E13.0, E13.00, E13.01, E05
HR_AC_GASTRO_PL	Acute gastrointestinal complications	ICD-10: K72.0, B15, B16, B17, B19.0, B19.11, B19.21, K85, J09.X3, J10.2, J11.2
HR_AC_HEMATO_PL	Acute hematological complications	ICD-10: D65, I82.210, I82.290, I82.220, I82.4, I82.6, I82.A1, I82.B1, I82.C1, D76.1, D76.2, D69.3, I26, D57.0, D57.01, D57.02, D57.21, D57.211, D57.212, D57.41, D57.411, D57.412, D57.81, D57.811, D57.812
HR_PULM_EMBOL_PL	Pulmonary embolism diagnosis	ICD-10: I26
HR_CARDITIS_PL	Carditis diagnosis	ICD-10: A39.50, B37.6, I01.0, I01.1, I01.2, I30, I33, I40, I51.4
HR_DIC_PL	Defibrination syndrome diagnosis	ICD-10: D65
HR_KETOACIDOSIS_PL	Ketoacidosis diagnosis	ICD-10: E08.1, E10.1, E13.1
HR_HYPRSMOLRTY_PL	Hyperosmolarity diagnosis	ICD-10: E08.0, E11.0, E13.0
HR_DIABET_COMA_PL	Diabetic coma diagnosis	ICD-10: E08.11, E08.641, E09.11, E09.641, E10.11, E11.01, E11.641, E13.11, E13.641, E15
HR_THYRD_STORM_PL	Thyroid storm diagnosis	ICD-10: E05.01, E05.11, E05.21, E05.31, E05.41, E05.81, E05.91
HR_RHABDOMYOL_PL	Rhabdomyolysis diagnosis	ICD-10: M62.82
HR_MYOSITIS_PL	Myositis diagnosis	ICD-10: M60
HR_MYOPATHY_PL	Critical illness myopathy diagnosis	ICD-10: G72.81
HR_GEST_DIABT_PL	History of gestational diabetes	ICD-10: Z86.32
HR_CHRONHTN_PL	Pregnancy complicated by preexisting hypertension with or without preeclampsia	ICD-10: O10 (O10.0 – O10.99), O11 (O11.1 - O11.9)
HR_PREECL_PL	Preeclampsia diagnosis during	ICD-10: O14 (O14.0– O14.05), O14.1 (O14.10– O14.15), O14.2 (O14.20-O14.25), O15 (O15.0-

	pregnancy or postpartum, with or without severe features, and including superimposed preeclampsia	O15.9), O14.9 (O14.90 – O14.95), O11 (O11.1-O11.9)
HR_PRCLSEVERE_PL	Preeclampsia with severe features	ICD-10: O14.1 (O14.10– O14.15), O14.2 (O14.20-O14.25), O15 (O15.0-O15.9)
HR_HELLP_PL	HELLP syndrome	ICD-10: O14.2 (O14.20-O14.25)
HR_GESTHTN_PL	Gestational hypertension (new onset) without proteinuria	ICD-10: O13 (O13.0-O13.9)

Any underlying medical conditions for the infant included any blood disorder, diabetes, acute or chronic heart failure diagnosis, cardiac arrest, acute or chronic heart disease (congenital), cancer, immune disorder, acute or non-acute renal failure, acute or non-acute liver failure, liver disease, asthma, lung disease (not asthma), altered mental status, encephalopathy, meningitis, anoxic brain damage, encephalitis or myelitis, coma, critical illness polyneuropathy, cerebral infarction, cerebral hemorrhage, cerebral edema, acute or chronic neurologic disease, arterial or venous embolism diagnosis, acute endocrine complications, acute gastrointestinal complications, acute hematological complications, pulmonary embolism, carditis, defibrillation syndrome, ketoacidosis, hyperosmolarity, diabetic coma, thyroid storm, rhabdomyolysis, myositis, or critical illness myopathy. For pregnant women/mothers, additional conditions included history of gestational diabetes, pregnancy complicated by preexisting hypertension with or without preeclampsia, preeclampsia diagnosis during pregnancy or postpartum, with or without severe features, and including superimposed preeclampsia, preeclampsia with severe features, HELLP syndrome, or gestational hypertension (new onset) without proteinuria.